| Molecular Formula | C12H8N2O7V.3H2O |
| Molar Mass | 397.189 |
| Solubility | DMSO: >10mg/mL |
| Appearance | solid |
| Color | gray |
| Storage Condition | -20°C |
| In vitro study | VO-OHpic is a small molecule compound that specifically inhibits the enzymatic activity of PTEN cells (PTEN sequentially activates downstream targets Akt and FoxO3a). Glucose uptake by adipocytes was significantly enhanced with VO-OHpic inhibition of PTEN. PTEN inhibitors accelerate wound repair of fibroblasts. VO-OHpic inhibition of cell viability, cell proliferation and colony formation and induction of senescence-associated β-galactosidase activity in Hep3B cells (low expressing PTEN), the effect was weak in PLC/PRF/5 cells (high expression of PTEN) and not in PTEN-negative SNU475 cells. |
| In vivo study | VO-Ohpic significantly inhibited tumor growth in tumor-bearing (xenograft of Hep3B cells) mice. Injection of VO-Ohpic into C57BL6 mice 30 minutes prior to KCl-induced cardiac arrest significantly increased their survival and cardiac function indicators LVPmax, dP/dt max and sustained benefit. VO-OHpic also significantly increased lactate clearance rate, lower blood glucose levels. |
| WGK Germany | 3 |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.518 ml | 12.588 ml | 25.177 ml |
| 5 mM | 0.504 ml | 2.518 ml | 5.035 ml |
| 10 mM | 0.252 ml | 1.259 ml | 2.518 ml |
| 5 mM | 0.05 ml | 0.252 ml | 0.504 ml |
| biological activity | VO-Ohpic is an effective PTEN (phosphatase and tensin homolog) inhibitor with IC50 of 35 nM. |
| target | TargetValue PTEN (Cell-free say) 35 nM |
| Target | Value |
| PTEN (Cell-free assay) | 35 nM |
| in vitro study | VO-OHpic is a small molecule compound that specifically inhibits PTEN cell enzyme activity (PTEN can activate downstream targets Akt and FoxO3a in turn). After inhibiting PTEN with VO-OHpic, the glucose absorption of adipocytes was significantly enhanced. PTEN inhibitors accelerate wound repair of fibroblasts. VO-OHpic inhibits cell viability, cell proliferation and colony formation, and induces senescence-related β-galactosidase activity in Hep3B cells (low expression of PTEN). The effect is relatively weak in PLC/PRF/5 cells (high expression of PTEN), but not in PTEN-negative SNU475 cells. |
| in vivo studies | VO-Ohpic significantly inhibit tumor growth in mice with tumors (xenografts of Hep3B cells). Injecting VO-Ohpic into C57BL6 mice 30 minutes before KCl-induced cardiac arrest significantly increased survival and cardiac function indicators LVPmax, dP/dt max and continued to benefit. VO-OHpic also significantly increased lactate clearance and lowered blood sugar levels. |